



Comparison: 1 Capsaicin versus placebo

Outcome: 1 Pain VAS 0-100




Comparison: 1 Capsaicin versus placebo

Outcome: 2 Percentage change in pain VAS




Comparison: 1 Capsaicin versus placebo

Outcome: 3 Pain (0 to 4) change from baseline at 4 weeks




Comparison: 1 Capsaicin versus placebo

Outcome: 4 Physician global (-1 to 3) at 4 weeks




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 1 Pain VAS 0-100




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 2 Lequesne algofunctional index




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 3 Disability VAS 0-100




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 4 Daily dose of NSAIDs (diclofenac equivalents)




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 5 Days on NSAIDs




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 6 Cumulative dose of NSAIDs (diclofenac equivalents) over days 45-90




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 7 Resumption of NSAIDs at day 60




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 8 Resumption of NSAIDs at end of treatment period




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 9 Require total hip replacement




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 10 Pain VAS 0-100 grouped by joint




Comparison: 2 Avocado/Soybean Unsaponifiables 300mg versus placebo

Outcome: 11 Participants (n) reported adverse events




Comparison: 3 Avocado/Soybean Unsaponifiables 600mg versus placebo

Outcome: 1 Pain VAS 0-100




Comparison: 3 Avocado/Soybean Unsaponifiables 600mg versus placebo

Outcome: 2 Lequesne algofunctional index




Comparison: 3 Avocado/Soybean Unsaponifiables 600mg versus placebo

Outcome: 3 Daily dose of NSAIDs (diclofenac equivalents)




Comparison: 3 Avocado/Soybean Unsaponifiables 600mg versus placebo

Outcome: 4 Days on NSAIDs




Comparison: 3 Avocado/Soybean Unsaponifiables 600mg versus placebo

Outcome: 5 Participants (n) reported adverse events



Comparison: 4 Harpaophytum versus diacerhein

Outcome: 1 Pain VAS 0-100 change from baseline at 120 days




Comparison: 4 Harpaophytum versus diacerhein
 Outcome: 2 Use of analgesics (acetominophen / caffeine)

| Study or sub-category | Harpagophytum | | Diacehein | | MD IV, Fixed, 95% CI | Weigh % |
|---|---------------|--------------|-----------|--------------|-------------------------|------------|
| | N | Mean (SD) | N | Mean (SD) | | |
| 1 At 30 days | | | | | | |
| Leban 2000 | 50 | 11.35 (0.00) | 42 | 12.96 (0.00) | | |
| Subtotal (95% CI) | 50 | | 42 | | | |
| Heterogeneity: not applicable | | | | | | |
| Test for overall effect: not applicable | | | | | | |
| 2 At 60 days | | | | | | |
| Leban 2000 | 50 | 21.08 (0.00) | 42 | 32.46 (0.00) | | |
| Subtotal (95% CI) | 50 | | 42 | | | |
| Heterogeneity: not applicable | | | | | | |
| Test for overall effect: not applicable | | | | | | |
| 3 At 120 days | | | | | | |
| Leban 2000 | 50 | 39.72 (0.00) | 42 | 59.55 (0.00) | | |
| Subtotal (95% CI) | 50 | | 42 | | | |
| Heterogeneity: not applicable | | | | | | |
| Test for overall effect: not applicable | | | | | | |
| Total (95% CI) | 150 | | 126 | | | |
| Heterogeneity: not applicable | | | | | | |
| Test for overall effect: not applicable | | | | | | |

-100 -50 0 50 100
 Favours devil's claw Favours diacerhein


Comparison: 4 Harpaophytum versus diacerhein

Outcome: 3 Use of NSAIDs (diclofenac)




Comparison: 4 Harpaophytum versus diacerhein

Outcome: 4 Pain VAS 0-100 change from baseline at 120 days




Comparison: 5 Rosa canina versus placebo

Outcome: 1 Relief of pain (0 to 4) at 3 months




Comparison: 5 Rosa canina versus placebo

Outcome: 2 Use of analgesics (paracetamol equivalents) at 3 months




Comparison: 5 Rosa canina versus placebo


Outcome: 3 Relief of joint stiffness (0 to 4)




Comparison: 5 Rosa canina versus placebo
Outcome: 4 Participants (n) reported adverse events



Comparison: 5 Rosa canina versus placebo
Outcome: 5 Participants (n) reported improvement of joint pain




Comparison: 5 Rosa canina versus placebo
Outcome: 6 Responders (improvement in at least one domain)




Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo

Outcome: 1 WOMAC pain score


Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo

Outcome: 2 WOMAC stiffness score




Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo


Outcome: 3 WOMAC physical function score

Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo

Outcome: 4 Pain VAS 0-100 at 14 days


Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo

Outcome: 5 Physical function VAS 0-100 at 14 days




Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo

Outcome: 6 Patient assessment of efficacy VAS 0-100




Comparison: 6 *Salix purpurea* x *daphnoides* (willow bark) versus placebo


Outcome: 7 Physician assessment of efficacy VAS 0-100 at 42 days



Comparison: 6 Salix purpurea x daphnoides (willow bark) versus placebo
 Outcome: 8 WOMAC pain score adjusted for baseline scores




Comparison: 7 Salix purpurea x daphnoides (willow bark) versus diclofenac
 Outcome: 1 WOMAC pain score




Comparison: 7 *Salix purpurea* x *daphnoides* (willow bark) versus diclofenac

Outcome: 2 WOMAC stiffness score


Comparison: 7 *Salix purpurea* x *daphnoides* (willow bark) versus diclofenac

Outcome: 3 WOMAC physical function scores




Comparison: 7 *Salix purpurea* x *daphnoides* (willow bark) versus diclofenac

Outcome: 4 Patient assessment of efficacy VAS 0-100




Comparison: 7 *Salix purpurea* x *daphnoides* (willow bark) versus diclofenac

Outcome: 5 Physician assessment of efficacy VAS 0-100 at 42 days




Comparison: 8 SKI306X versus placebo

Outcome: 1 Pain VAS 0-100 change from baseline




Comparison: 8 SKI306X versus placebo

Outcome: 2 Lequesne algofunctional index change from baseline




Comparison: 8 SKI306X versus placebo

Outcome: 3 Participants (n) reported adverse events




Comparison: 9 SKI306X versus diclofenac

Outcome: 1 Pain VAS 0-100 change from baseline




Comparison: 9 SKI306X versus diclofenac

Outcome: 2 Lequesne algofunctional index change from baseline




Comparison: 9 SKI306X versus diclofenac

Outcome: 3 Participants (n) reported adverse events




Comparison: 10 Phytodolor N versus placebo

Outcome: 1 Pain on movement (0 to 3)




Comparison: 10 Phytodolor N versus placebo

Outcome: 2 Enduring pain (0 to 3)




Comparison: 10 Phytodolor N versus placebo

Outcome: 3 Use of NSAIDS (diclofenac)




Comparison: 10 Phytodolor N versus placebo

Outcome: 4 Cumulative dose analgesics (acetaminophen mg) over 3 weeks




Comparison: 10 Phytodolor N versus placebo

Outcome: 5 Use of rescue medication (any type, not standardised)




Comparison: 10 Phytodolor N versus placebo

Outcome: 6 Finger-ground distance (centimeters)




Comparison: 10 Phytodolor N versus placebo

Outcome: 7 Mobility limitations (0 to 3)




Comparison: 10 Phytodolor N versus placebo

Outcome: 8 Reported adverse events




Comparison: 11 EV.EXT77 (ginger) versus placebo

Outcome: 1 WOMAC pain score




Comparison: 11 EV.EXT77 (ginger) versus placebo

Outcome: 2 WOMAC stiffness score




Comparison: 11 EV.EXT77 (ginger) versus placebo

Outcome: 3 WOMAC physical function score




Comparison: 11 EV.EXT77 (ginger) versus placebo


Outcome: 4 WOMAC total score




Comparison: 11 EV.EXT77 (ginger) versus placebo
 Outcome: 5 SF-12 physical component summary score




Comparison: 11 EV.EXT77 (ginger) versus placebo
 Outcome: 6 SF-12 mental component summary score




Comparison: 11 EV.EXT77 (ginger) versus placebo
Outcome: 7 Pain after walking 50 feet VAS 0-100



Comparison: 11 EV.EXT77 (ginger) versus placebo
Outcome: 8 Patient global (1 to 5)




Comparison: 11 EV.EXT77 (ginger) versus placebo
Outcome: 9 Participants (n) reported adverse events (all)




Comparison: 11 EV.EXT77 (ginger) versus placebo

Outcome: 10 Daily dose of analgesics (acetaminophen mg) over 6 weeks




Comparison: 12 Zintona EC (ginger) versus placebo

Outcome: 1 Pain on movement VAS 0-100 at 12 weeks




Comparison: 12 Zintona EC (ginger) versus placebo


Outcome: 2 Handicap VAS 0-100 at 12 weeks



Comparison: 12 Zintona EC (ginger) versus placebo
 Outcome: 3 Participants (n) reported adverse events (all)




Comparison: 13 Boswellia-curcumin versus placebo
 Outcome: 1 Pain free walking time (minutes)




Comparison: 13 Boswellia-curcumin versus placebo

Outcome: 2 Pain on passive movement (0 to 3)




Comparison: 13 Boswellia-curcumin versus placebo

Outcome: 3 Pain on active movement (0 to 3)




Comparison: 14 Boswellia serrata versus placebo

Outcome: 1 Pain (0 to 3)




Comparison: 14 Boswellia serrata versus placebo

Outcome: 2 Loss of movement (0 to 3)




Comparison: 14 Boswellia serrata versus placebo

Outcome: 3 Swelling (0 to 3)




Comparison: 14 Boswellia serrata versus placebo

Outcome: 4 Participants (n) reported adverse effects




Comparison: 15 Arnica versus ibuprofen

Outcome: 1 Pain VAS 0-100




Comparison: 15 Arnica versus ibuprofen

Outcome: 2 28 painful joint count change from baseline




Comparison: 15 Arnica versus ibuprofen

Outcome: 3 Intensity of morning stiffness (1 to 5) change from baseline




Comparison: 15 Arnica versus ibuprofen

Outcome: 4 Duration of morning stiffness (1 to 5) change from baseline




Comparison: 15 Arnica versus ibuprofen

Outcome: 5 Hand alгоfunctional index (0 to 3)




Comparison: 15 Arnica versus ibuprofen

Outcome: 6 Cumulative dose of analgesics (acetaminophen mg) over 3 weeks




Comparison: 15 Arnica versus ibuprofen

Outcome: 7 Participants (n) reported adverse events




Comparison: 16 Cat's claw versus placebo


Outcome: 1 Pain at night (assumed VAS 0-10)




Comparison: 16 Cat's claw versus placebo
Outcome: 2 Pain at rest (assumed VAS 0-10)



Comparison: 16 Cat's claw versus placebo
Outcome: 3 Participants (n) reported adverse events




Comparison: 17 Comfrey versus placebo
Outcome: 1 Pain at rest VAS 0-100 change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 2 Pain on movement VAS 0-100 change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 3 WOMAC pain score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 4 WOMAC stiffness score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 5 WOMAC physical function score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 6 WOMAC total score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 7 SF-36 physical component summary score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 8 SF-36 mental component summary score change from baseline




Comparison: 17 Comfrey versus placebo

Outcome: 9 Participants (n) reported adverse events




Comparison: 18 Reumalex versus placebo

Outcome: 1 AIMS2 arthritis pain score change from baseline



Comparison: 18 Reumalex versus placebo

Outcome: 2 AIMS2 arthritis pain score change from extended baseline



Comparison: 18 Reumalex versus placebo

Outcome: 3 Modified Ritchie score change from baseline

